Copenhagen, Denmark, September 21, 2022 /PRNewswire/ — The BioInnovation Institute (BII), an international commercial, not-for-profit foundation that creates and accelerates world-class life sciences research, today announces that it has entered into a collaboration with Imperial College London on a new translational project under the Framework their bio to start studio program. The program aims to encourage the creation of new life science start-ups based on research by world-class scientists for the benefit of people and society.
As part of the cooperation Molly Stevens FREng FRS, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, will lead a translational research project in the field of HealthTech. The aim of the project is to provide a transformative approach to the early detection and monitoring of debilitating diseases through the development of an ultra-sensitive target-agnostic biosensor platform. Research will focus on diseases that could potentially address major global public health challenges. The technology is intended to be deployed as a low-cost diagnostic platform, enabling artificial intelligence-based evaluation of molecular fingerprints to inform clinical decisions with the aim of slowing disease progression and improving treatment plans.
BII supports the project with a grant of up to DKK 6.5 million per year for a project duration of up to three years and with business development expertise, intellectual property support, an investor network and infrastructure.
The Bio Studio program is a recently established BII program with the aim of building and operating a leading facility for the creation of life science companies Europe. The present project follows a collaboration with the European Molecular Biology Laboratory (EMBL) in Heidelberg, announced in June this year.
Markus Herrgård, Chief Technology Officer at BII, commented on the collaboration: said: “We are delighted to be collaborating with Prof. Stevens and her team on the Bio Studio program….
